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In pemphigus vulgaris, treatment with systemic glu-
cocorticosteroids is life saving; it may, however, cause
severe side e¡ects, including death. A patient with pem-
phigus vulgaris and myasthenia gravis was treated for
approximately ¢ve years with the cholinomimetic
Mestinon (pyridostigmine bromide), Imuran (azathio-
prine), and a topical corticosteroid gel before the need
to introduce systemic glucocorticosteroids. Because
activation of keratinocyte acetylcholine receptors also
has been shown to abolish pemphigus IgG^induced
acantholysis in cultured keratinocyte monolayers, a
clinical trial of Mestinon was initiated in patients with
active pemphigus vulgaris, pemphigus foliaceus, and
paraneoplastic autoimmune multiorgan syndrome (also
known as paraneoplastic pemphigus). First results indi-
cate that nonsteroidal treatment of pemphigus is possi-
ble. Mestinon may be used to slow down progression of
the disease and to treat mild cases with chronic lesions
on limited areas. Stimulation of the keratinocyte^ acet-
ylcholine axis may lead to a therapeutic e¡ect through
any of the following mechanisms: (1) stimulating kera-
tinocyte cell-to-cell attachment; (2) accelerating re-
epithelialization; and (3) competing with the disease-
causing pemphigus antibodies, preventing them from
attachment to keratinocytes. Glucocorticosteroids and
various types of steroid-sparing drugs used to treat
pemphigus exhibit cholinergic side e¡ects, including
e¡ects on expression and function of keratinocyte adhe-
sion molecules, that are very similar to those produced
by the cholinomimetic drugs. Further elucidation of the
mechanisms underlying therapeutic e⁄cacy of antia-
cantholytics may shed light on the immunopharmaco-
logical mechanisms of pemphigus antibody^induced
acantholysis. Key words: acantholysis/acetylcholine receptor/
keratinocyte/Mestinon/myasthenia gravis/pemphigus vulgaris.
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T
hemajor objective of pemphigus research is develop-
ment of a safer treatment regimen. Pemphigus pa-
tients need drugs that can replace the gluco-
corticosteroid hormones (GS) that many of them
must take for life. GS therapy is life saving, but
patients su¡er from severe side e¡ects and complications. Alterna-
tive therapies that foster keratinocyte adhesion and/or speci¢cally
antagonize the e¡ects of pemphigus antibodies are desperately
needed. In the past, I developed treatment modalities (Grando,
1988; Grando et al, 1989d; Grando et al, 1990; Grando, 1992) that,
in addition to GS, included: (1) ex-vivo ¢ltration of patients’ blood
through carbon adsorbent, followed by plasmapheresis and ad-
ministration of cytostatic drugs, to eliminate disease-causing
pemphigus autoantibodies and suppress the synthesis of new
ones; (2) antiproteases, antikinins, and antileukotrienes (querce-
tin, aprotinin, and e-aminocaproic acid) to inactivate mediators
of in£ammation present in pemphigus blister £uid (Grando et al,
1987; Grando et al, 1989a; Grando et al, 1989c); and (3) doxycycline
to suppress the cell-mediated autoimmunity component of pem-
phigus’ immunopathogenesis (Grando et al, 1989b). Unfortunately,
none of these approaches allowed complete replacement of GS in
pemphigus patients. Recent research results, however, suggest
that novel antiacantholytic therapies may be developed by mi-
micking the antiacantholytic e¡ects of GS with nonsteroidal
drugs acting at the acetylcholine receptors (AChR) expressed by
keratinocytes (Grando et al, 2001). Keratinocyte adhesion is con-
trolled, in part, by acetylcholine (ACh), a cytokine-like chemical
(i.e., a cytotransmitter) that is locally produced by keratinocytes
(reviewed in Grando, 1997). ACh and its congeners (i.e., cholino-
mimetic drugs) can reverse pemphigus antibody^induced
acantholysis both in vitro (Grando and Dahl, 1993) and in vivo.1
Taking into consideration that GS can prevent but not reverse
pemphigus IgG-induced acantholysis (Swanson and Dahl, 1983),
these observations suggest that cholinomimetic drugs might be a
novel and more e⁄cient treatment for pemphigus. A case of pem-
phigus vulgaris (PV) that improved by cigarette smoking (Mehta
and Martin, 2000), studies showing negative correlation between
smoking and pemphigus (Brenner et al, 2001), and successful use
of nicotinamide as a steroid-sparing agent in pemphigus (Chaf-
¢ns et al, 1993) hint that this expectation is realistic for the follow-
ing reasons: (1) cigarette smoke contains cholinomimetic
nicotine; and (2) nicotinamide exhibits cholinomimetic e¡ects
(Romanenko, 1987) due to both stimulation of ACh release
(Koeppen et al, 1997) and inhibition of acetylcholinesterase
(AChE) (Stoytcheva and Zlatev, 1996). The rationale behind the
use of cholinergic drugs also stems from data demonstrating in-
volvement of keratinocyte AChR in pemphigus pathophysiology
(reviewed in Grando, 2000). On these premises, I hypothesized
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that cholinomimetics should abort or alleviate pemphigus. This
therapeutic approach should be successful even if keratinocyte
AChR are not targeted by disease-causing pemphigus antibodies
in a particular patient, because ACh and its muscarinic and nico-
tinic congeners can accelerate the rate of keratinocyte migration,
thus fostering re-epithelialization of pemphigus erosions
(Grando, 1997). As a test of this hypothesis, an open clinical trial
of a nontoxic AChE inhibitor, Mestinon (pyridostigmine bro-
mide), was initiated approximately two years ago in the derma-
tology clinic of the University of California at Davis. In the
clinical trial, Mestinon was chosen as a systemic cholinomimetic
drug because an index patient with both PV and myasthenia
gravis (MG) had successfully treated her pemphigus for almost
¢ve years, without using systemic GS, by manipulating her daily
dose of Mestinon from 180 to 360 mg, taking Imuran (azathiopr-
ine) and applying a glucocorticoid gel to fresh lesions.
RESULTS
The results of the clinical trial reported herein were obtained in
eight patients with active pemphigus without MG, including all
three major clinical forms of autoimmune pemphigus. The diag-
nosis of pemphigus was based on the results of comprehensive
clinical and histological examinations, together with immunolo-
gical studies, following standard protocols (Beutner et al, 1985).
This study had been approved by the University of California,
Davis, Human Subjects Review Committee.
Treatment of PV without systemic GS in the index
patient The index patient was a 39-year-old Ashkenazi Jewish
female with both PV and MG. At the age of 18, she developed
arthralgias and was given the diagnosis of lupus erythematosus
on the basis of positive results of ANA, nDNA and VDRL
antibody tests and LE cell preparations. She was treated with
NSAIDs until the symptoms resolved by the age of 20 and the
above tests became normal. After that, she had two pregnancies
that resulted in miscarriages during the ¢rst trimester due to
large subchorionic hemorrhages associated with borderline titers
of anticardiolipin antibodies. A third pregnancy was complicated
by another large subchorionic hemorrhage in the ¢rst trimester,
but the pregnancy continued and resulted in a normal vaginal
delivery by induction. At the age of 30, she developed symp-
toms of nasal speech at ¢ve months into the next pregnancy.
Three weeks prior to delivery of the second child, she developed
ptosis of the left eyelid. Three days after delivery, her speech
became much more slurred and she developed di⁄culty in deep
breathing. The ¢nding of an anti-AChR antibody at the titer of
25 and the results of a Tensilon test con¢rmed the clinical diag-
nosis of MG. A chest CTscan revealed a hyperplastic thymus, but
was negative for thymoma. She was started on 60 mg Mestinon
three times a day. Initial improvement was followed by an in-
crease of muscular weakness, di⁄culty swallowing, and worsen-
ing of slurred speech. At the age of 31, she had a thymectomy,
which was preceded by ¢ve sessions of plasmapheresis. The
postoperative course was relatively uncomplicated. Since then,
she has been controlling her myasthenia symptoms with daily
doses of Mestinon ranging between 120 and 210 mg.
At the age of 33, this patient developed the initial symptoms of
PV. She ¢rst noticed occasional bleeding and in£ammation of her
gums that did not disturb her much. Approximately one year
later, multiple white and ulcerated areas on gingival crest and
crevice, which bled readily, were found during an annual dental
checkup. Super¢cial mucosa could be wiped away, indicating the
presence of a positive direct Nikolskiy sign (Grando et al, 2003). A
crusted erosion of approximately 11 cm that bled easily upon
mechanical stimulation was also found behind the right ear. She
was referred to an oral surgeon, who made an incisional biopsy of
the right posterior mandibular alveolar mucosa. The histopa-
thological study revealed suprabasilar acantholysis consistent
with PV. This clinical and histological diagnosis was con¢rmed
by the results of immunological studies performed at the
Beutner Laboratories (Bu¡alo, New York) during exacerbation
of her skin disease. Intercellular antibodies were found in the
perilesional skin by direct immuno£uorescence, and low-titer
intercellular antibodies were demonstrated by indirect
immuno£uorescence.
During the ¢rst four years, the course of PV in this patient was
rather mild. One to two new lesions on oral mucosa and/or skin
would develop monthly and heal quickly, either spontaneously or
upon the use of topical GS. These symptoms developed in the
background of a maintenance dose of Mestinon. At the age of
37, the patient developed a moderately severe exacerbation
characterized by the appearance of approximately 50 small, 1^2-
cm-diameter, bullous lesions on skin and oral mucosa soon after
these preceding events: (1) ¢ve sessions of intravenous gamma-
globulin injections over a period of one week in an attempt to
improve myasthenia symptoms; (2) slight tapering of Mestinon
because improvement of myasthenia had been achieved; and (3)
severe emotional stress. Systemic GS were not initiated because
of the threat of a myasthenic crisis. Instead, the patient was
treated with plasmapheresis. For several years after that, in
addition to the maintenance dose of Mestinon, she took Imuran
at a daily dose of 150 mg and used 0.05% clobetasol propionate
gel (Temovate) on new pemphigus lesions that occasionally
appeared on her skin and oral mucosa. Her pemphigus antibody
titer remained at 1/320, as determined by indirect immuno-
£uorescence using monkey esophagus as a substrate. She
infrequently developed side e¡ects from the Mestinon, such as
skin £ushes, sweating, and diarrhea. Otherwise, she had a good
quality of life. After approximately ¢ve years of treatment, the
lesions on her skin and oral mucosa began to develop more
frequently, which required initiation of prednisone therapy to
control her PV. Currently, she takes 20 mg prednisone per day.
First results of clinical trial of mestinon in pemphigus
patients The intriguing aspect of the management of the index
patient was that conventional GS therapy was not instituted for the
¢rst ¢ve years of her disease. Although it is possible to maintain
pemphigus patients in remission using immunosuppressive drugs
without GS (Lever and Schaumburg-Lever, 1977; Lever and
Schaumburg-Lever, 1984; Stemm and Thivolet, 1995), initial
treatment of PV relies on systemic GS in a high dose (Holubar
and Fellner, 1986; Muller and Stanley, 1990; Carson et al, 1996). To
the best of my knowledge, neither Imuran alone nor Imuran in
combination with plasmapheresis and/or Temovate gel has ever
been reported to allow complete avoidance of systemic GS at the
initial stage of pemphigus treatment. Therefore, I considered
Mestinon as a therapeutic agent that ameliorated the natural
course of disease in this patient, and I initiated an open clinical
trial. An overall goal was to evaluate the e⁄cacy of Mestinon in
terminating the spread of pemphigus erosion and in fostering re-
epithelialization of already existing lesions. Both new patients with
pemphigus who had not received GS and established patients with
disease exacerbation on the background of immunosuppressive
therapy were enrolled. Patients with generalized, life-threatening
forms of disease whose well being might be jeopardized by any
delay in initiating systemic GS therapy were excluded from the
study, as were children less then than 16 years of age, pregnant
women, and nursing mothers.
During approximately two years of the clinical trial, eight
patients with active pemphigus used Mestinon for at least four
weeks (Table 1). They took Mestinon tablets at a total daily dose
of 360 mg. Three PV patients (patients 1, 6, and 8) and a patient
with paraneoplastic autoimmune multiorgan syndrome [(PAMS;
also known as paraneoplastic pemphigus (Nguyen et al, 2001)]
showed a very good response (the patients are hereafter referred
to as the responders). The other three PV patients and one
pemphigus foliaceus patient showed no signi¢cant improve-
ment. Among the responders, two PV patients (patients 1 and 6)
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and the PAMS patient were able to control their disease using
Mestinon alone. One responder demonstrated a direct strong
interrelationship between the use of Mestinon and the ability to
control his PV (patient 1; Fig 1). After achieving stable control, he
discontinued Mestinon. Approximately two weeks later, he
reported redness and itching/burning sensations at the sites of the
fully healed pre-existing lesions, which were followed by
microvesiculation and advert lesional weeping. At this point,
Mestinon was restarted. Within several days, the progression of
the lesions aborted and the erosions began to dry. It took about
three weeks for the lesions to completely heal, after which the
patient slowly tapered his Mestinon daily dose to zero. He has
remained free from lesions for almost 18 months without any
need of medication for pemphigus. This patient provides a ‘‘proof
of concept’’case of the e⁄cacy of Mestinon in pemphigus because
he showed (1) rapid improvement of his disease at the time the
drug was taken, although this might be attributed to a
coincidental spontaneous improvement of the disease; (2) rapid
exacerbation of PV after the drug had been abruptly
discontinued; and (3) rapid reversal of the £are-up of his PV after
the drug had been restarted.
DISCUSSION
Possible mechanisms of the therapeutic e⁄cacy of Mestinon
in pemphigus The ¢rst results of the clinical trial of Mestinon
are encouraging, indicating that this cholinomimetic can be used
to slow down progression of disease in patients with acute
pemphigus and to treat mild cases with limited areas of
nonhealing erosions. No controls needed to be allocated to
standard therapy because the success of the new treatment could
be judged against the well-known standard prognosis. The course
of pemphigus is well characterized, and it is well known that
practically all pemphigus patients relapse if systemic GS are
withdrawn during the disease’s active phase (Herbst and
Bystryn, 2000). In a classic example, Dr. Morton established the
e⁄cacy of anesthesia by demonstrating that one anesthetized
patient felt none of the excruciating pain that had invariably
accompanied surgery. Therefore, the ‘‘proof of concept’’ result
with Mestinon in the PV patient shown in Fig 1 indicates that
an approach to the treatment of pemphigus that employs
cholinomimetics is practical. The obtained results do raise a
question, however: How can Mestinon suppress acantholysis in
pemphigus? The answer may provide a new lead in solving the
pemphigus enigma.
It is well known that Mestinon increases tissue levels of
endogenous ACh because of the reversible inhibition of AChE
that hydrolyzes ACh (Taylor, 1985). Keratinocytes actively
metabolize ACh, employing the synthesizing enzyme choline
acetyltransferase (ChAT) and the degrading enzyme AChE, and
they use ACh as an autocrine and paracrine hormone or
cytotransmitter (reviewed in Grando, 1997). Additionally,
Mestinon can act directly on keratinocyte AChR because it has
Table1. Summary of the Results of Open Trial of Mestinon in Pemphigus Patientsa






during the trial Outcome of the trial
Systemic treatment
after the trial
1 45/M PV positive positive GS , IS none permanent remission taper Mestinon over 3 months
2 64/F PV positive positive GS, IS GS no improvement GS , IS
3 38/M PV positive positive GS, IS GS (lower dose) no improvement GS, IS
4 33/M PF ND positive GS GS (lower dose) no improvement GS, IS
5 65/M PAMS positive negative GS, IS none temporary remission GS (lower dose); Mestinon
6 53/F PV positive positive none none improvement Mestinon
7 51/F PV positive positive GS, IS GS, IS no improvement GS , IS
8 82/M PV positive ND GS, IS GS (lower dose) improvement GS (lower dose); Mestinon
aAbbreviations: GS, glucocorticosteroid hormones; IF, direct and/or indirect immuno£uorescence; IS, immunosuppressors; ND, not done; PAMS, paraneoplastic auto-
immune multiorgan syndrome; PF, pemphigus foliaceus; PV, pemphigus vulgaris.
Figure1. Treatment of Pemphigus Vulgaris
with Mestinon. (A) Before treatment. (B) Three
months on Mestinon. (C) Three weeks after dis-
continuing Mestinon. (D) One month after restart-
ing Mestinon.
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been shown to interact directly with cholinergic receptors as a
weak agonist capable of inducing desensitization, both alone and
when combined with ACh (Akaike et al, 1984). Human epidermal
keratinocytes express both the ACh-gated ion channelsthat is,
the neuronal-type nicotinic AChR (nAChR), which can
comprise a3, a5, a7, a9, a10, b2, and b4 subunits (Grando et al,
1995a; Grando et al, 1996; Nguyen et al, 2000a; Nguyen et al,
2000b; Sgard et al, 2002)and G protein^coupled muscarinic
AChR (mAChR) of the M1, M3, M4, and M5 subtypes (Ndoye
et al, 1998). Oral keratinocytes also express the M2 mAChR
subtype, but lack M1 (Arredondo et al, 2003). Mestinon can
interact with the ACh-ionic channel complex, blocking it in
open conformation, via at least three distinct, although possibly
interacting, mechanisms: (1) a weak agonist action; (2) the
formation of desensitized receptor-complex intermediates; and
(3) the alteration of the conductance properties of active
channels (Albuquerque et al, 1984; Pascuzzo et al, 1984).
As will be detailed below, stimulation of the keratinocyte
ACh axis with Mestinon might lead to a therapeutic e¡ect in
pemphigus through any one or a combination of the following
mechanisms: (1) stimulating keratinocyte cell-to-cell attachment;
(2) promoting faster re-epithelialization; and (3) competing with
the disease-causing pemphigus antibodies, preventing them from
attachment to keratinocyte AChR.
ACh as a cytotransmitter regulating keratinocyte adhesion
Mestinon might intercede at the intracellular signaling pathway
that mediates the acantholytic e¡ects of pemphigus antibodies. The
binding of pemphigus IgG to keratinocytes leads to acantholysis
through activation of a biochemical cascade that involves activation
of phospholipase C, production of inositol 1,4,5-trisphosphate, Ca2þ
in£ux and rapid transient increase of intracellular Ca2þ , changes in
the intracellular cAMP/cGMP ratios, and activation and translo-
cation of protein kinase C from the cytosol to the particulate/
cytoskeleton fractions (Grando et al, 1988; Esaki et al, 1995;
Lyubimov et al, 1995; Seishima et al, 1995; Osada et al, 1997). The
other messenger systems used by ACh are the same as those used
by pemphigus IgG (Grando et al, 1988; Esaki et al, 1995; Lyubimov
et al, 1995; Seishima et al, 1995; Osada et al, 1997). In e¡ect, activation
of keratinocyte AChR restores normal morphology of pemphigus
IgG^treated acantholytic keratinocytes in cultures (Grando and
Dahl, 1993). Therefore, a signal sent by ACh through activating
keratinocyte AChR can override the signal evoked by pemphigus
antibody binding to keratinocytes.
It has been convincingly demonstrated that nicotinic and
muscarinic drugs exhibit dramatic e¡ects on cell-to-cell and cell-
to-substrate cohesion of human epidermal and oral keratinocytes
(Grando and Dahl, 1993; Grando et al, 1993; Grando et al, 1995a;
Nguyen et al, 2000a; Nguyen et al, 2000b). Blocking AChR with
either muscarinic or nicotinic antagonistsatropine and
mecamylamine, respectivelyin both cases results in acantholysis
in keratinocyte monolayers (Grando and Dahl, 1993; Grando et al,
1995a). Notably, systemic use of atropine has exacerbated skin and
oral blistering in one of our patients with PV. Results obtained in
our pilot studies strongly suggest that cholinergic control of
keratinocyte adhesion is exerted through receptor-mediated
modi¢cations of both expression and phosphorylation of adhesion
molecules.2 For instance, we demonstrated that the acantholytic
e¡ect of atropine is associated with increased phosphorylation of
cadherins in DJM-1 cell monolayers. Phosphorylation of classical
and desmosomal cadherins is known to be involved in regulation
of cell-to-cell adhesion (Parrish et al, 1990; Stappenbeck et al, 1994;
Pasdar et al, 1995; Kowalczyk et al, 1999), and pemphigus IgG^
induced acantholysis involves phosphorylation of desmoglein 3 and
its dissociation from plakoglobin (Aoyama et al, 1999). Interestingly,
ligation of a9 AChR has been reported to induce phosphorylation
of cell membrane proteins with molecular weights of 120 and 220
kDa (Szonyi et al, 1999). These may represent adhesion molecules,
such as the 120-kDa E-cadherin (Mareel et al, 1991) and the 220-
kDa desmoplakin 2 (Joly et al, 1994). Thus, Mestinon might
stimulate keratinocyte adhesion by activating classical and
desmosomal cadherins, including e¡ects on the phosphorylation
status of an adhesion molecule.
ACh as a cytotransmitter regulating re-epithelialization
Re-epithelialization of pemphigus erosions is a self-sustained
process that can be regulated by endogenously secreted media-
tors such as ACh. ACh can facilitate keratinocyte outgrowth in
culture. Both muscarinic and nicotinic agonists produce a
stimulatory e¡ect on keratinocyte spreading and migration,
whereas inhibiting ACh synthesis and blocking AChR abrogate
lateral migration of human keratinocytes (Grando et al, 1993;
Grando et al, 1995a). In neurons, too, ACh regulates the direction
of nerve growth cone extension, and blocking ACh signaling
inhibits nerve outgrowth (Zheng et al, 1994). To characterize
cholinergic control of the metamorphosis of keratinocytes
during wound healing, we developed an in vitro model of skin
re-epithelialization that allows accurate evaluation of drug e¡ects
on lateral migration of keratinocytes (Grando et al, 1993).The cells
exposed to carbachol, a muscarinic and nicotinic agonist and
reversible AChE inhibitor, moved signi¢cantly farther compared
to nonexposed keratinocytes.3 The response to carbachol was
dose dependent and was seen starting from the nanomolar con-
centrations of the drug. Both the nicotinic antagonist mecamy-
lamine and the muscarinic antagonist atropine abrogated the
carbachol-induced keratinocyte migration. Recent results
obtained in in vivo skin-wounding experiments in AChR
knockout mice indicate that M4 mAChR plays a central role in
mediating cholinergic control of keratinocyte migration by
regulating integrin expression.4 Therefore, the role of Mestinon
as a stimulator of a basic regulatory pathway of keratinocyte
migration that might help re-epithelialize pemphigus erosions
merits further consideration.
Figure 2. Hypothetical plan of treatment
of pemphigus in the post-corticosteroid
era.
2Grando SA, Arredondo J, ChernyavskyA, KitajimaY, NguyenVT: Me-
chanisms of pharmacologic regulation of keratinocyte adhesion by choli-
nergic drugs. J Invest Dermatol 119:225, abstr. #107, 2002
3LeeTX, Horton RM, Grando SA: Cholinergic drugs stimulate chemo-
kinesis of human epidermal keratinocytes. J Invest Dermatol 106:841, abstr.
#215, 1996
4Chernyavsky A, Arredondo J, Nguyen VT, Ndoye A, Zia S, Wess J,
Grando SA: Molecular mechanisms of stimulatory e¡ect of M4 muscarinic
acetylcholine receptor on keratinocyte migration. J Invest Dermatol 119:225,
abtsr. #108, 2002
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Immunopathological similarities of PV and MG Although
experimental PV in neonatal mice can be induced with
autoantibodies to the adhesion molecules desmoglein 1 and
desmoglein 3 (Amagai et al, 1992; Arteaga et al, 2002), results
obtained in my laboratory show that pemphigus symptoms can
be induced in neonatal mice lacking desmoglein 3 with passive
transfer of the PV IgG that lack desmoglein 1 antibody (Nguyen
et al, 1998). The pool of disease-causing pemphigus antibodies
includes the autoantibodies to keratinocyte AChR, which are
found in approximately 85% of patients (Nguyen et al, 1998).
The antigenic speci¢cities of pemphigus antibodies include the
novel human a AChR (Nguyen et al, 2000b), with mixed,
nicotinic and muscarinic pharmacology (Elgoyhen et al, 1994),
and pemphaxin, a human annexin that binds ACh (Nguyen
et al, 2000c). Indeed, pemphigus antibodies have been shown to
compete directly with a cholinergic radioligand, [3H]atropine,
for binding to keratinocytes (Grando and Dahl, 1993), indicating
that binding of anti-AChR IgG to keratinocytes can produce an
immunopharmacological e¡ect.
We reported a pemphigus patient with MG who developed an
autoantibody binding to keratinocyte a3 nAChR.5 Myasthenia
and pemphigus may therefore share a common immuno-
pathological pathway. MG is caused by autoantibodies against
the nAChR expressed at the neuromuscular junction to mediate
neuromuscular transmission (reviewed in Conti-Tronconi et al,
1994). These antibodies are heterogeneous and can be detected in
approximately 85% of patients (Tzartos et al, 1982). It is not
uncommon to ¢nd in some myasthenic patients clinical
manifestations of pemphigus (reviewed in Kaplan and Callen,
1983). In such patients, autoantibodies can be directed against
both desmosomal and neuromuscular antigens (McKee et al,
1978; Beutner et al, 2002). Likewise, AChR accumulate at both
desmosomal and neuromuscular junctions (Engel et al, 1977;
Grando et al, 1995b). Recently, Dr. Beutner’s group proposed that
in pemphigus associated with malignancies, autoimmunity may
serve primarily as a defense mechanism against such systemic
complications, although some forms of it, such as the
autoantibodies to AChR, can cause the death of patients with
PAMS (Beutner et al, 2002). Approximately 70% of MG patients
have thymitis, and approximately 10% develop thymoma
(reviewed in Marx et al, 1992). Like myasthenia, pemphigus may
be associated with a tumor of the thymus, and pemphigus,
thymoma, and myasthenia may coexist in the same patient
(reviewed in Younus and Ahmed, 1990; Sherer et al, 1997). This
raises the possibility that two seemingly disparate clinical
conditions such as PV and MG may have similar immuno-
pathological mechanisms. In addition to mAChR (Maslinski
Table 2. Cholinergic ‘‘Side-e¡ects’’ of Drugs Used to Treat Pemphigus
GS Via their genomic e¡ects, GS upregulate the cholinergic enzymes ChATand AChE (Kaufman et al, 1988) [although this e¡ect may vary
depending on the cell type (Tria et al, 1992; Hortnagl et al, 1993)] and increase expression of both nAChRs and mAChRs (Ben-
Baruch et al, 1981; Marquardt et al, 1982; Braun et al, 1993), which is proposed as a possible explanation for some of their therapeutic
e¡ects (Vilquin et al, 1992).The non-genomic e¡ects of GS are mediated by virtue of their ability to attach in a non-competitive manner
to a site of ACh-gated ion channels on the outer cell membrane and alter ACh-induced inward currents (Inoue and Kuriyama, 1989;
Bouzat and Barrantes, 1993; Ke and Lukas, 1996; Nurowska and Ruzzier, 1996).
Cyclophosphamide Behaves like a classic nicotinic cholinergic ligand, because it speci¢cally binds to the ligand-binding sites of both the muscle- and the
neuronal-types nAChRs (Minker and Blazso, 1987), but not mAChR (Peroutka, 1987), and also reversibly inhibits AChE activity in a
dose-dependent manner (al-Jafari et al, 1995).
Cyclosporin Augments synthesis of ACh (Esqui¢no et al, 1997), and also interferes with protein kinase C-mediated signal transduction from
mAChR (Hoecker et al, 1994).
Gold Aurano¢n and other gold-containing compounds inhibit ACh-mediated e¡ects on non-neuronal cells (Ohlstein and Horohonich,
1989; Fontaine et al, 1991).
Nicotinamide Increases tissue levels of choline [a metabolic precursor of ACh and pharmacologic agonist of AChRs [Sterz, 1986; Ulus, 1988]],
leading to increased ACh release (Koeppen et al, 1996; Koeppen et al, 1997), and also regulates mAChR-coupled Kþ channel
(Higashida et al, 1995; Higashida et al, 1996). Nicotinic acid (syn: niacin) acts as a competive inhibitor of AChE (Stoytcheva and Zlatev,
1996), whereas its ester exhibits an ACh-like e¡ect on smooth muscle contraction (Winkelman et al, 1969).
Tetracyclines Tetracycline, chlortetracycline, minocycline and doxycycline cause a concentration-dependent inhibition of ACh release (Anadon
and Martinez-Larranaga, 1987).
Tranilast Inhibits cholinergic neurotransmissions of guinea pig bronchial muscle in vitro (Kamikawa, 1989).
Aprotinin Inhibits activity of AChE (Chasapakis et al, 1968)the enzyme that hydrolyses not onlyACh but also various peptides, just like a
professional trypsin-like endopeptidase (Small et al, 1987).
Quercetin Inhibits ACh release (Lutterodt, 1989).
Heparin Enhances agonist binding to an inhibitory-type of mAChRs, due to disruption of the mAChR-G protein interactions (Wang et al,
1996), interferes with intracellular signalling from the stimulatory-type mAChR, due to inhibition of inositol 1,4,5-trisphosphate
(Olianas and Onali, 1997), and also inhibits AChR aggregation (Hopf and Hoch, 1997) and solubilizes AChE from the cell
membrane (Talesa et al, 1993).
Suramin Competitive agonist of nAChRs (Henning et al, 1992).
Quinine Causes a closed-channel block of nAChR (Ssieb et al, 1996), inhibits mAChR-induced Kþ currents (Chen et al, 1993), and also acts as
both non-competitive inhibitor of AChE (Stoytcheva and Zlatev, 1996) and a high a⁄nity competitive inhibitor of choline transport
(Porter et al, 1992).
Strychnine Speci¢c pharmacologic ligand of the novel a AChR that was ¢rst found in rat (Elgoyhen et al, 1994), and then cloned by us from
human keratinocytes (Nguyen et al, 2000b).
Arsenic compounds Inhibit mAChRs (Fonseca et al, 1991) and both cholinergic enzymes, ChAT and AChE (Kobayashi et al, 1987; Sheabar andYannai,
1989).
5Grando SA, George PM, Dahl MV, Conti-Tronconi BM: Antibody
against keratinocyte nicotinic acetylcholine receptor in patient with coex-
istent pemphigus foliaceus, myasthenia gravis and thymoma. J Invest Der-
matol 102:609, abstr. #511, 1994
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et al, 1990; Rinner et al, 1990), the thymus expresses both the
‘‘muscle’’ a1 and the ‘‘neuronal’’ or ‘‘epithelial’’ a3, a5, a7, and b4
types of nAChR subunits (Wheatley et al, 1992; Navaneetham et
al, 1997; Mihovilovic and Butterworth-Robinette, 2001).
Therefore, these two autoimmune diseases might develop as a
result of autoimmune responses triggered by autosensitization
against the AChR expressed by the thymus. In myasthenia, such
sensitization would focus on the AChR expressed by myocytes;
in pemphigus, on the AChR expressed by keratinocytes. On the
basis of this model, only those patients with thymoma/thymitis
would be expected to develop a second or third disease whose
antibodies are directed toward the epitope of thymic AChR
shared by the AChR expressed in the muscle or skin. Future
studies are needed to determine whether the keratinocyte self
antigens targeted by autoantibodies in pemphigus patients with
MG are the same as those targeted in patients with pemphigus
without thymoma/thymitis and/or myasthenia.
CHOLINERGIC SIDE EFFECTS OF DRUGS USED TO
TREAT PEMPHIGUS
The enigma of pemphigus stems from the fact that the doses of
GS required to stop blistering, as well as to sustain remission in
many patients, are usually much higher compared to those ordi-
narily used to control other autoimmune diseases (Myles and
Daly, 1974). In pemphigus, GS may work by (1) inhibiting anti-
body synthesis; (2) suppressing in£ammation, especially eosino-
philic spongiosis; and (3) stopping acantholysis via direct
pharmacologic e¡ect on keratinocyte, given that the addition of
GS to skin organ cultures treated with pemphigus antibodies pre-
vents pemphigus IgG^induced acantholysis (Swanson and Dahl,
1983; Je¡es et al, 1984).The last of the three mechanisms just listed,
reported independently by two di¡erent groups, deserves parti-
cular attention because the use of very large doses of methylpred-
nisolone (‘‘pulse therapy’’) suppresses pemphigus in patients
within 48 hours (Werth, 1996), and it is believed that the thera-
peutic e¡ect is mediated by a direct pharmacologic e¡ect of GS
on keratinocytes (Hashimoto et al, 1984).We recently reported that
PV IgG and methylprednisolone exhibit reciprocal e¡ects on the
transcription, translation, and phosphorylation of keratinocyte
adhesion molecules.6 Methylprednisolone upregulated transcrip-
tion of the genes encoding desmoglein 3, desmocollins, plakophi-
lin, E-cadherin, p-cadherin, a-catenin, several protein phospha-
tases, protease inhibitors, and lipocortins, and also suppressed
PVIgG-induced phosphorylation of adhesion molecules. There-
fore, GS may block PVIgG-induced acantholysis via a complex
of intracellular genomic and nongenomic events, some of which
are also involved in mediating signaling from keratinocyte
AChR. Further elucidation of the mechanisms underlying the
therapeutic activity of GS and other drugs that have been or are
successfully used to treat pemphigus may shed light on the phar-
macologic mechanisms mediating pemphigus IgG^induced
acantholysis.
Nonsteroidal treatments of pemphigus reported to date include
the following drugs (in chronological order): quinine and strych-
nine (reviewed in Kartamyshev, 1949), organic arsenic compounds
(Oppenheim, 1927), suramin (also known as germanin or ne-
phuride) (Veiel, 1931), vitamin D (Ludy and DeValin, 1932), meth-
otrexate (Lever and Goldberg, 1969), azathioprine (Wol¡ and
Schreiner, 1969), cyclophosophamide (Krain et al, 1972), gold (Pen-
neys et al, 1973), dapsone (Haim and Friedman-Birnbaum, 1978),
heparin (Mashkilleyson, 1985), cyclosporine (Balda and Rosenz-
weig, 1986), quercetin and doxycyline (Grando, 1988), aprotinin
and e-aminocaproic acid (Grando, 1992), nicotinamide and tetra-
cycline (Cha⁄ns et al, 1993), minocycline (Sawai et al, 1995),
p-aminomethylbenzoic acid (Dobrev et al, 1996), mycophenolate
mofetil (Enk and Knop, 1997), and tranilast (Miyamoto andTaka-
hashi, 1997). Surprisingly, a single mechanism of action common
for GS and many of the above listed nonsteroid drugs is choliner-
gic activity (Table 2). Is this a mere coincidence, or does the phar-
macologic modulation of keratinocyte ACh axis provide a
common denominator of antiacantholytic action of these drugs?
The post-corticosteroid era in the treatment of pemphigus:
it is possible The results of the clinical trial of Mestinon
suggest that nonsteroidal treatment of PV patients can be
achieved by pharmacologically stimulating keratinocyte cell-to-
cell adhesion through the keratinocyte ACh axis. Future studies
in this direction will create an opportunity for pemphigus
patients to obtain safer treatment of their disabling condition. A
successful GS-free treatment regimen should be able to e⁄ciently
block the intracellular signaling elicited by pemphigus antibody
binding to keratinocytes. Both an immediate and a more distant
solution to this problem should be sought. An immediate
solution will be to identify a pharmacological substitute for, or
an adjunct to, GS that can e⁄ciently control acantholysis. A
more distant solution will be to prevent acantholysis by
inhibiting synthesis of disease-causing pemphigus antibodies. In
addition to their use as a tolerogen for T cell tolerization in the
future, the sequences of the pathogenic epitopes of self antigens
can be used for ex-vivo selective immunoadsorption of disease-
causing pemphigus antibodies from patients’ blood. Thus,
successful development of nonsteroidal treatment of pemphigus
will animate patient management, as shown in Fig. 2.
This work was supported by a research grant from the Robert Leet & Clara Guthrie
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